• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

COVID-19 患者静脉血栓栓塞的预测因素:COVID-19 巴西登记处的结果。

Predictors of venous thromboembolism in COVID-19 patients: results of the COVID-19 Brazilian Registry.

机构信息

Universidade Federal de Minas Gerais, Av. Presidente Antônio Carlos, 6627, Belo Horizonte, Brazil.

University Hospital, Universidade Federal de Minas Gerais, Avenida Professor Alfredo Balena, 110, Santa Efigênia, Belo Horizonte, MG, CEP 30130-100, Brazil.

出版信息

Intern Emerg Med. 2022 Oct;17(7):1863-1878. doi: 10.1007/s11739-022-03002-z. Epub 2022 Jun 1.

DOI:10.1007/s11739-022-03002-z
PMID:35648280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9156830/
Abstract

Previous studies that assessed risk factors for venous thromboembolism (VTE) in COVID-19 patients have shown inconsistent results. Our aim was to investigate VTE predictors by both logistic regression (LR) and machine learning (ML) approaches, due to their potential complementarity. This cohort study of a large Brazilian COVID-19 Registry included 4120 COVID-19 adult patients from 16 hospitals. Symptomatic VTE was confirmed by objective imaging. LR analysis, tree-based boosting, and bagging were used to investigate the association of variables upon hospital presentation with VTE. Among 4,120 patients (55.5% men, 39.3% critical patients), VTE was confirmed in 6.7%. In multivariate LR analysis, obesity (OR 1.50, 95% CI 1.11-2.02); being an ex-smoker (OR 1.44, 95% CI 1.03-2.01); surgery ≤ 90 days (OR 2.20, 95% CI 1.14-4.23); axillary temperature (OR 1.41, 95% CI 1.22-1.63); D-dimer ≥ 4 times above the upper limit of reference value (OR 2.16, 95% CI 1.26-3.67), lactate (OR 1.10, 95% CI 1.02-1.19), C-reactive protein levels (CRP, OR 1.09, 95% CI 1.01-1.18); and neutrophil count (OR 1.04, 95% CI 1.005-1.075) were independent predictors of VTE. Atrial fibrillation, peripheral oxygen saturation/inspired oxygen fraction (SF) ratio and prophylactic use of anticoagulants were protective. Temperature at admission, SF ratio, neutrophil count, D-dimer, CRP and lactate levels were also identified as predictors by ML methods. By using ML and LR analyses, we showed that D-dimer, axillary temperature, neutrophil count, CRP and lactate levels are risk factors for VTE in COVID-19 patients.

摘要

先前评估 COVID-19 患者静脉血栓栓塞症(VTE)风险因素的研究结果并不一致。我们的目的是通过逻辑回归(LR)和机器学习(ML)方法来研究 VTE 的预测因素,因为它们具有互补性。这项来自巴西一个大型 COVID-19 注册中心的队列研究纳入了来自 16 家医院的 4120 名成年 COVID-19 患者。有症状的 VTE 通过客观成像来确诊。LR 分析、基于树的提升和装袋方法用于研究入院时变量与 VTE 的关联。在 4120 名患者中(55.5%为男性,39.3%为危重症患者),有 6.7%的患者确诊为 VTE。多变量 LR 分析显示,肥胖(OR 1.50,95%CI 1.11-2.02);曾经吸烟(OR 1.44,95%CI 1.03-2.01);手术距入院时间≤90 天(OR 2.20,95%CI 1.14-4.23);腋窝温度(OR 1.41,95%CI 1.22-1.63);D-二聚体比参考值上限高 4 倍以上(OR 2.16,95%CI 1.26-3.67)、乳酸(OR 1.10,95%CI 1.02-1.19)、C 反应蛋白(CRP,OR 1.09,95%CI 1.01-1.18);中性粒细胞计数(OR 1.04,95%CI 1.005-1.075)是 VTE 的独立预测因素。心房颤动、外周血氧饱和度/吸入氧分数(SF)比值和预防性抗凝是保护性因素。入院时的体温、SF 比值、中性粒细胞计数、D-二聚体、CRP 和乳酸水平也被 ML 方法确定为预测因素。通过使用 ML 和 LR 分析,我们表明 D-二聚体、腋窝温度、中性粒细胞计数、CRP 和乳酸水平是 COVID-19 患者 VTE 的危险因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af8c/9156830/f568897669ab/11739_2022_3002_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af8c/9156830/f0c223d1ec5d/11739_2022_3002_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af8c/9156830/b2fbb2560bb9/11739_2022_3002_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af8c/9156830/f568897669ab/11739_2022_3002_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af8c/9156830/f0c223d1ec5d/11739_2022_3002_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af8c/9156830/b2fbb2560bb9/11739_2022_3002_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af8c/9156830/f568897669ab/11739_2022_3002_Fig3_HTML.jpg

相似文献

1
Predictors of venous thromboembolism in COVID-19 patients: results of the COVID-19 Brazilian Registry.COVID-19 患者静脉血栓栓塞的预测因素:COVID-19 巴西登记处的结果。
Intern Emerg Med. 2022 Oct;17(7):1863-1878. doi: 10.1007/s11739-022-03002-z. Epub 2022 Jun 1.
2
Venous thrombosis, thromboembolism, biomarkers of inflammation, and coagulation in coronavirus disease 2019.2019冠状病毒病中的静脉血栓形成、血栓栓塞、炎症生物标志物及凝血
J Vasc Surg Venous Lymphat Disord. 2021 Jul;9(4):835-844.e4. doi: 10.1016/j.jvsv.2020.11.006. Epub 2020 Nov 12.
3
Biomarkers for the prediction of venous thromboembolism in critically ill COVID-19 patients.用于预测危重症 COVID-19 患者静脉血栓栓塞症的生物标志物。
Thromb Res. 2020 Dec;196:308-312. doi: 10.1016/j.thromres.2020.09.017. Epub 2020 Sep 15.
4
Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors.COVID-19 患者接受抗栓治疗时的静脉血栓栓塞症的系统评估:发生率和 D-二聚体作为预测因素的作用。
J Thromb Thrombolysis. 2020 Jul;50(1):211-216. doi: 10.1007/s11239-020-02146-z.
5
Predictive value of inflammatory and coagulation biomarkers for venous thromboembolism in COVID-19 patients.炎症和凝血生物标志物对 COVID-19 患者静脉血栓栓塞的预测价值。
Clin Hemorheol Microcirc. 2023;83(4):387-395. doi: 10.3233/CH-221664.
6
COVID-19 Infection in Critically Ill Patients Carries a High Risk of Venous Thrombo-embolism.危重症患者感染新型冠状病毒肺炎后发生静脉血栓栓塞的风险很高。
Eur J Vasc Endovasc Surg. 2021 Apr;61(4):628-634. doi: 10.1016/j.ejvs.2020.12.015. Epub 2020 Dec 23.
7
Venous thromboembolism after spontaneous intracerebral hemorrhage and the status quo of anticoagulation in this population: A retrospective casecontrol study from a tertiary hospital in China.自发性脑出血后静脉血栓栓塞症及该人群抗凝现状:来自中国一家三级医院的回顾性病例对照研究。
Clin Neurol Neurosurg. 2023 Aug;231:107839. doi: 10.1016/j.clineuro.2023.107839. Epub 2023 Jun 19.
8
Venous thromboembolism and COVID-19: a single center experience from an academic tertiary referral hospital of Northern Italy.静脉血栓栓塞症和 COVID-19:来自意大利北部一家学术型三级转诊医院的单中心经验。
Intern Emerg Med. 2021 Aug;16(5):1141-1152. doi: 10.1007/s11739-020-02550-6. Epub 2020 Nov 8.
9
Clinical characteristics and risk factors for symptomatic venous thromboembolism in hospitalized COVID-19 patients: A multicenter retrospective study.COVID-19 住院患者有症状静脉血栓栓塞的临床特征和危险因素:一项多中心回顾性研究。
J Thromb Haemost. 2021 Apr;19(4):1038-1048. doi: 10.1111/jth.15261. Epub 2021 Feb 24.
10
Venous thromboembolism in COVID-19 patients and prediction model: a multicenter cohort study.COVID-19 患者静脉血栓栓塞症及其预测模型:一项多中心队列研究。
BMC Infect Dis. 2022 May 13;22(1):462. doi: 10.1186/s12879-022-07421-3.

引用本文的文献

1
Predictors of venous thromboembolic events in hospitalized patients with COVID-19.新型冠状病毒肺炎住院患者静脉血栓栓塞事件的预测因素
J Thromb Thrombolysis. 2025 Apr;58(4):485-496. doi: 10.1007/s11239-025-03078-2. Epub 2025 Mar 10.
2
Development of a Decision Support Tool for Anticoagulation in Critically Ill Patients Admitted for SARS-CoV-2 Infection: The CALT Protocol.用于收治新型冠状病毒2019感染的重症患者抗凝治疗的决策支持工具的开发:CALT方案
Biomedicines. 2023 May 23;11(6):1504. doi: 10.3390/biomedicines11061504.
3
COVID-19 and Pulmonary Thrombosis-An Unresolved Clinical Puzzle: A Single-Center Cohort Study.

本文引用的文献

1
Clinical characteristics and outcomes of venous thromboembolism in patients hospitalized for COVID-19: Systematic review and meta-analysis.因新冠肺炎住院患者静脉血栓栓塞症的临床特征及预后:系统评价与荟萃分析
Thromb Update. 2021;2:100037. doi: 10.1016/j.tru.2021.100037. Epub 2021 Mar 19.
2
Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register.COVID-19 患者接受血栓预防治疗的住院死亡率低:来自多中心观察性 START-COVID 登记处的数据。
Intern Emerg Med. 2022 Jun;17(4):1013-1021. doi: 10.1007/s11739-021-02891-w. Epub 2022 Jan 1.
3
2019冠状病毒病与肺血栓形成——一个尚未解决的临床难题:一项单中心队列研究
J Clin Med. 2022 Nov 29;11(23):7049. doi: 10.3390/jcm11237049.
Predictive scores for the diagnosis of Pulmonary Embolism in COVID-19: A systematic review.
预测 COVID-19 中肺栓塞诊断的评分:系统评价。
Int J Infect Dis. 2022 Feb;115:93-100. doi: 10.1016/j.ijid.2021.11.038. Epub 2021 Nov 27.
4
Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.COVID-19 住院高危患者中治疗剂量肝素与标准预防剂量或中剂量肝素预防血栓的疗效和安全性:HEP-COVID 随机临床试验。
JAMA Intern Med. 2021 Dec 1;181(12):1612-1620. doi: 10.1001/jamainternmed.2021.6203.
5
Construction of a Risk Prediction Model for Hospital-Acquired Pulmonary Embolism in Hospitalized Patients.构建住院患者医院获得性肺栓塞风险预测模型。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211040868. doi: 10.1177/10760296211040868.
6
Pulmonary embolism and COVID-19: A comparative analysis of different diagnostic models performance.肺栓塞与 COVID-19:不同诊断模型性能的比较分析。
Am J Emerg Med. 2021 Dec;50:526-531. doi: 10.1016/j.ajem.2021.09.004. Epub 2021 Sep 20.
7
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.新冠肺炎危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4.
8
ABC-SPH risk score for in-hospital mortality in COVID-19 patients: development, external validation and comparison with other available scores.COVID-19患者院内死亡的ABC-SPH风险评分:开发、外部验证及与其他现有评分的比较
Int J Infect Dis. 2021 Sep;110:281-308. doi: 10.1016/j.ijid.2021.07.049. Epub 2021 Jul 24.
9
Association between risk of venous thromboembolism and mortality in patients with COVID-19.COVID-19 患者静脉血栓栓塞风险与死亡率的关系。
Int J Infect Dis. 2021 Jul;108:543-549. doi: 10.1016/j.ijid.2021.06.005. Epub 2021 Jun 6.
10
Anticoagulation and In-Hospital Mortality From Coronavirus Disease 2019: A Systematic Review and Meta-Analysis.新型冠状病毒肺炎抗凝治疗与住院病死率的系统评价和荟萃分析。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211008999. doi: 10.1177/10760296211008999.